15 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Untitled document
    15
    1. karim2001khoury 19 Feb 2026
      Oncogenic RIT1 mutations in lung adenocarcinoma

      [Paper-level Aggregated] PMCID: PMC4150988

      Evidence Type(s): Oncogenic, Functional, Predictive

      Justification: Oncogenic: The text indicates that RIT1 mutations, particularly in the switch II domain, are associated with the ability to induce cellular transformation and tumor formation, suggesting their role as oncogenes in lung adenocarcinoma. Functional: The study demonstrates that mutated RIT1 can activate signaling pathways (MEK/ERK and PI3K/AKT) and induce cellular transformation, indicating a functional impact of these mutations on cellular behavior. Predictive: The presence of RIT1 mutations, particularly in the context of lung adenocarcinoma, may predict the activation of specific signaling pathways and the potential for tumor formation, as evidenced by the transformation assays conducted in the study.

      Gene→Variant (gene-first): RIT1(6016):F82L RIT1(6016):M90I RIT1(6016):p.M90I KRAS(3845):G12V EGFR(1956):L858R RIT1(6016):Q40 RIT1(6016):Q40L RIT1(6016):Q79L NA:alanine 77 RIT1(6016):p.A77P RIT1(6016):p.A77S RIT1(6016):p.R122L

      Genes: RIT1(6016) KRAS(3845) EGFR(1956) NA

      Variants: F82L M90I p.M90I G12V L858R Q40 Q40L Q79L alanine 77 p.A77P p.A77S p.R122L

      CIViC paper-level aggregated PMC4150988
    2. karim2001khoury 19 Feb 2026
      Given the prevalence of RIT1 mutation in primary human lung adenocarcinomas, we hypothesized that human lung adenocarcinoma cell lines may also harbor mutations in RIT1 and that identification of these cell lines would f

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Oncogenic, Diagnostic

      Justification: Oncogenic: The passage discusses the presence of the p.M90I mutation in lung adenocarcinoma cell lines and its association with human primary lung adenocarcinomas, indicating that this somatic variant contributes to tumor development or progression. Diagnostic: The p.M90I mutation is mentioned as being seen in human primary lung adenocarcinomas, suggesting its role in defining or classifying the disease.

      Gene→Variant (gene-first): 6016:p.M90I

      Genes: 6016

      Variants: p.M90I

      CIViC paragraph-level PMC4150988 Oncogenic Diagnostic
    3. karim2001khoury 19 Feb 2026
      RIT1 mutation is mutually exclusive with mutations in other RAS/RTK-pathway genes, so we hypothesized that RIT1 may activate PI3K and MEK. To investigate the signaling changes induced by mutated RIT1, we expressed wild-t

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 9

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage discusses how the RIT1 Q40L mutation contributes to tumor development by activating MEK and ERK pathways, indicating its role in oncogenic signaling. Functional: The variant Q40L alters the molecular function of RIT1, as it induces phosphorylation of MEK and ERK, demonstrating a change in biochemical activity associated with the mutation.

      Gene→Variant (gene-first): 6016:Q40L

      Genes: 6016

      Variants: Q40L

      CIViC paragraph-level PMC4150988 Oncogenic Functional
    4. karim2001khoury 19 Feb 2026
      To test whether mutated RIT1 is capable of inducing cellular transformation, we expressed wild-type or mutated RIT1 cDNA constructs in NIH3T3 cells and assayed the ability of these cells to form colonies in soft agar. A

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 7

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage discusses how mutated RIT1 variants, including Q79L, G12V, and L858R, induce cellular transformation and tumor formation, indicating their role in tumor development. Functional: The passage describes the ability of specific RIT1 mutations to induce colony formation in soft agar, suggesting that these variants alter the molecular function of RIT1 in a way that promotes transformation.

      Gene→Variant (gene-first): 3845:G12V 1956:L858R 6016:Q40 6016:Q40L 6016:Q79L

      Genes: 3845 1956 6016

      Variants: G12V L858R Q40 Q40L Q79L

      CIViC paragraph-level PMC4150988 Oncogenic Functional
    5. karim2001khoury 19 Feb 2026
      We surveyed recent exome sequencing data from other diverse cancer types to determine whether RIT1 is mutated in malignancies other than lung adenocarcinoma. Most tumor types had no mutations, or rare RIT1 variants of un

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 6

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the presence of the RIT1 p.M90I variant in different cancer types, indicating its association with malignancies, which supports its use in defining or classifying disease subtypes. Oncogenic: The mention of somatic RIT1 mutations in myeloid malignancies and their overlap with mutations in lung adenocarcinoma suggests that these variants contribute to tumor development or progression.

      Gene→Variant (gene-first): 6016:F82L 6016:M90I 6016:p.M90I

      Genes: 6016

      Variants: F82L M90I p.M90I

      CIViC paragraph-level PMC4150988 Diagnostic Oncogenic
    6. karim2001khoury 19 Feb 2026
      All seven samples with switch II domain RIT1 mutations lacked oncogenic driver mutations in EGFR, KRAS, BRAF, ERBB2, HRAS, NRAS and MAP2K1. This pattern of mutational mutual exclusivity is consistent with the possibility

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 5

      Evidence Type(s): Oncogenic

      Justification: Oncogenic: The passage suggests that RIT1 switch II domain mutations, including p.R122L, may function as oncogenes in lung adenocarcinoma, indicating a role in tumor development or progression.

      Gene→Variant (gene-first): 6016:p.R122L

      Genes: 6016

      Variants: p.R122L

      CIViC paragraph-level PMC4150988 Oncogenic
    7. karim2001khoury 19 Feb 2026
      Recurrent alteration of RIT1 alanine 77 was also observed; one of the ten mutated samples from this analysis harbored a p.A77P mutation and an additional TCGA sample (TCGA-73-4666) harbored a p.A77S mutation. TCGA-73-466

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 4

      Evidence Type(s): Diagnostic, Predisposing

      Justification: Diagnostic: The passage discusses the recurrent alteration of RIT1 alanine 77 and mentions that one of the mutated samples harbored a p.A77P mutation, indicating its association with tumor classification. Predisposing: The passage suggests that p.A77S may represent a rare germline variant, indicating a potential inherited risk for disease, although it is noted to be unlikely.

      Gene→Variant (gene-first): NA:alanine 77 6016:p.A77P 6016:p.A77S

      Genes: NA 6016

      Variants: alanine 77 p.A77P p.A77S

      CIViC paragraph-level PMC4150988 Diagnostic Predisposing
    8. karim2001khoury 19 Feb 2026
      In total, non-synonymous somatic mutations of RIT1 were identified in 10/413 (2.4%) lung adenocarcinomas subjected to whole exome sequencing (Figure 1a, Supplementary Table 1). Mutations in RIT1 consisted of missense mut

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 3

      Evidence Type(s): Oncogenic

      Justification: Oncogenic: The passage discusses non-synonymous somatic mutations of RIT1, including the p.M90I variant, in the context of lung adenocarcinomas, indicating that these mutations contribute to tumor development or progression.

      Gene→Variant (gene-first): 6016:p.M90I

      Genes: 6016

      Variants: p.M90I

      CIViC paragraph-level PMC4150988 Oncogenic
    9. karim2001khoury 19 Feb 2026
      Given the prevalence of RIT1 mutation in primary human lung adenocarcinomas, we hypothesized that human lung adenocarcinoma cell lines may also harbor mutations in RIT1 and that identification of these cell lines would f

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Oncogenic, Diagnostic

      Justification: Oncogenic: The passage discusses the presence of the p.M90I mutation in lung adenocarcinoma cell lines and its association with human primary lung adenocarcinomas, indicating that this somatic variant contributes to tumor development or progression. Diagnostic: The p.M90I mutation is mentioned as being seen in human primary lung adenocarcinomas, suggesting its role in defining or classifying the disease.

      Gene→Variant (gene-first): 6016:p.M90I

      Genes: 6016

      Variants: p.M90I

      CIViC paragraph-level PMC4150988 Oncogenic Diagnostic
    10. karim2001khoury 19 Feb 2026
      RIT1 mutation is mutually exclusive with mutations in other RAS/RTK-pathway genes, so we hypothesized that RIT1 may activate PI3K and MEK. To investigate the signaling changes induced by mutated RIT1, we expressed wild-t

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 9

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage discusses how the RIT1 Q40L mutation contributes to tumor development by activating MEK and ERK pathways, indicating its role in oncogenic signaling. Functional: The variant Q40L alters the molecular function of RIT1, as it induces phosphorylation of MEK and ERK, demonstrating a change in biochemical activity associated with the mutation.

      Gene→Variant (gene-first): 6016:Q40L

      Genes: 6016

      Variants: Q40L

      CIViC paragraph-level PMC4150988 Oncogenic Functional
    11. karim2001khoury 19 Feb 2026
      To test whether mutated RIT1 is capable of inducing cellular transformation, we expressed wild-type or mutated RIT1 cDNA constructs in NIH3T3 cells and assayed the ability of these cells to form colonies in soft agar. A

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 7

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage discusses how mutated RIT1 variants, including Q79L, G12V, and L858R, induce cellular transformation and tumor formation, indicating their role in tumor development. Functional: The passage describes the ability of specific RIT1 mutations to induce colony formation in soft agar, suggesting that these variants alter the molecular function of RIT1 in a way that promotes transformation.

      Gene→Variant (gene-first): 3845:G12V 1956:L858R 6016:Q40 6016:Q40L 6016:Q79L

      Genes: 3845 1956 6016

      Variants: G12V L858R Q40 Q40L Q79L

      CIViC paragraph-level PMC4150988 Oncogenic Functional
    12. karim2001khoury 19 Feb 2026
      We surveyed recent exome sequencing data from other diverse cancer types to determine whether RIT1 is mutated in malignancies other than lung adenocarcinoma. Most tumor types had no mutations, or rare RIT1 variants of un

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 6

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the presence of the RIT1 p.M90I variant in different cancer types, indicating its association with malignancies, which supports its use in defining or classifying disease subtypes. Oncogenic: The mention of somatic RIT1 mutations in myeloid malignancies and their overlap with mutations in lung adenocarcinoma suggests that these variants contribute to tumor development or progression.

      Gene→Variant (gene-first): 6016:F82L 6016:M90I 6016:p.M90I

      Genes: 6016

      Variants: F82L M90I p.M90I

      CIViC paragraph-level PMC4150988 Diagnostic Oncogenic
    13. karim2001khoury 19 Feb 2026
      All seven samples with switch II domain RIT1 mutations lacked oncogenic driver mutations in EGFR, KRAS, BRAF, ERBB2, HRAS, NRAS and MAP2K1. This pattern of mutational mutual exclusivity is consistent with the possibility

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 5

      Evidence Type(s): Oncogenic

      Justification: Oncogenic: The passage suggests that RIT1 switch II domain mutations, including p.R122L, may function as oncogenes in lung adenocarcinoma, indicating a role in tumor development or progression.

      Gene→Variant (gene-first): 6016:p.R122L

      Genes: 6016

      Variants: p.R122L

      CIViC paragraph-level PMC4150988 Oncogenic
    14. karim2001khoury 19 Feb 2026
      Recurrent alteration of RIT1 alanine 77 was also observed; one of the ten mutated samples from this analysis harbored a p.A77P mutation and an additional TCGA sample (TCGA-73-4666) harbored a p.A77S mutation. TCGA-73-466

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 4

      Evidence Type(s): Diagnostic, Predisposing

      Justification: Diagnostic: The passage discusses the recurrent alteration of RIT1 alanine 77 and mentions that one of the mutated samples harbored a p.A77P mutation, indicating its association with tumor classification. Predisposing: The passage suggests that p.A77S may represent a rare germline variant, indicating a potential inherited risk for disease, although it is noted to be unlikely.

      Gene→Variant (gene-first): NA:alanine 77 6016:p.A77P 6016:p.A77S

      Genes: NA 6016

      Variants: alanine 77 p.A77P p.A77S

      CIViC paragraph-level PMC4150988 Diagnostic Predisposing
    15. karim2001khoury 19 Feb 2026
      In total, non-synonymous somatic mutations of RIT1 were identified in 10/413 (2.4%) lung adenocarcinomas subjected to whole exome sequencing (Figure 1a, Supplementary Table 1). Mutations in RIT1 consisted of missense mut

      [Paragraph-level] PMCID: PMC4150988 Section: RESULTS PassageIndex: 3

      Evidence Type(s): Oncogenic

      Justification: Oncogenic: The passage discusses non-synonymous somatic mutations of RIT1, including the p.M90I variant, in the context of lung adenocarcinomas, indicating that these mutations contribute to tumor development or progression.

      Gene→Variant (gene-first): 6016:p.M90I

      Genes: 6016

      Variants: p.M90I

      CIViC paragraph-level PMC4150988 Oncogenic
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC4150988/pdf/41388_2014_Article_BFonc2013581.pdf